Navigation Links
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Date:10/5/2007

the promising results seen to date, we strongly believe that SLx-4090 could play a significant role in the marketplace by providing clinicians another route to manage lipid disorders for patients who do not adequately respond to currently available treatment options."

Surface Logix is also exploring the use of SLx-4090 in other metabolic disorders, including obesity and diabetes.

SLx-4090 Phase 1 Repeat-Dose Study Design

The SLx-4090 Phase 1 repeat-dose study is a randomized, double-blind, placebo-controlled, dose escalating/dose decreasing study in 10 cohorts of 12 healthy male volunteers each. A variety of dosing regimens were included in the study. For subjects receiving SLx-4090, doses ranged from 25 mg to 200 mg, and dosing frequency in active and placebo arms ranged from once daily to three times daily. Treatment periods ranged from 5 to 14 days.

About SLx-4090 in Dyslipidemia

SLx-4090 is a novel microsomal triglyceride transfer protein (MTP) inhibitor being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream). Surface Logix designed SLx-4090 using its proprietary small molecule Pharmacomer(TM) technology to act specifically in the gastrointestinal (GI) tract to prevent the transport of fats through the intestinal wall. This unique feature of intestinal selectivity allows potent activity against fat uptake while avoiding toxicity at other sites of MTP expression in the body including the liver, heart, testis, ovary, and eye.

Dyslipidemia currently affects approximately 10% of the global population, with 25% of these patients having elevated triglyceride levels. In addition, there is an increasing prevalence and medical need for lipid-modifying drugs in obese patients and patients with type 2 diabetes, as a high proportion of type 2 diabetic patients have abnormal concentrations of lipoproteins. In the U.S., Japan and Europe, it is estimated that there are more than 240 million people wit
'/>"/>

SOURCE Surface Logix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- Environmental health advocates hope that U.S. FDA ... of bisphenol A (BPA), a synthetic sex hormone ... other illnesses, in time for Christmas. ,, ... scientist, Natural Resources Defense Council : "Just ... advice, FDA must rely on the advice of ...
(Date:12/14/2009)... CLAREMONT, Calif., Dec. 14 The ... College today released the analysis of social ... companies world-wide. The report contains a compilation ... the environmental and social reporting of the ... intent, and performance for both environmental and ...
(Date:12/14/2009)... Mass., Dec. 14 According to Millennium ... technology market intelligence, increased use of safety devices ... will be a key driver of the enteral ... Europe. MRG,s new US and European Markets ... that the giving set segment will experience the ...
Breaking Medicine Technology:Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Abbott Completes Visiogen Acquisition 5625 1Abbott Completes Visiogen Acquisition 5625 2Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27 2009 5620 1Penn team uses self assembly to make molecule sized particles with patches of charge 10447 1Penn team uses self assembly to make molecule sized particles with patches of charge 10447 2
(Date:12/14/2009)... now provides in-home caregivers who have been certified by the ... therapy, caregiver, and hospice services to San Francisco Bay Area ... ... (PRWEB) December 14, 2009 -- Professional HealthCare at Home, the ... care, including nursing, rehab, personal caregiver and hospice services, has ...
(Date:12/14/2009)... 14 Josie Raper, a 29 year-old mother from ... months with the help of the Dr. Siegal,s COOKIE DIET® ... Joy Fit Club segment on NBC,s Today Show. The Joy ... airs twice a month and salutes those who have lost ... and has kept it off for two years. ,, "The ...
(Date:12/14/2009)... Only about one in 2,000 people in the United ... of the unfortunate few. , Ms. Wilcox,s tumor was a ... those problems were mistaken for blocked sinuses. , "For several ... my nose," recalled the resident of Goldthwaite, a town of ... "I felt a fullness, but I didn,t take that as ...
(Date:12/14/2009)... the December issue of Mayo Clinic Proceedings , ... This retrospective study is the largest ever conducted in ... a serious disorder that disrupts the body,s normal production ... the bone marrow, leading to severe anemia, weakness, fatigue ... "In the past 20 years, management of primary myelofibrosis ...
(Date:12/14/2009)... long-term solution, researchers say , , MONDAY, Dec. 14 ... dislocations can benefit from a procedure that "sculpts" ... cadavers, new research suggests. , The study, ... American Journal of Sports Medicine , finds that ... that stabilize or reconstruct a shoulder joint by ...
Breaking Medicine News(10 mins):Health News:Caregivers with Professional HealthCare at Home Now Certified by the Alzheimer's Association 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2
... CITY, Feb. 11 Two Little Hands Productions --,creators ... public television,show designed to teach babies, toddlers and young ... debut its second season at this,year,s Toy Fair 2008 ... http://www.newscom.com/cgi-bin/prnh/20080211/LAM029 ), Like the original, series ...
... Feb. 11 MedThink Communications, an,innovator in ... has been retained by Salix Pharmaceuticals, Inc, ... product under development, an,orally disintegrating form of ... to market the orally disintegrating,metoclopramide tablet and ...
... found that one in twenty breast cancer web pages ... complementary or alternative medicine were fifteen times more likely ... the March 15, 2008 issue of CANCER, a peer-reviewed ... patients consult clinicians before taking action on breast cancer ...
... researchers led by Fred Hutchinson Cancer Research Center has ... ovarian tumors become resistant to treatment with commonly used ... describe their research online Feb. 10 in the journal ... of ovarian-cancer cells from women with inherited mutations in ...
... & Shop,Supermarket Company, following a voluntary recall by Chattem, ... from sale. Chattem,is recalling these products based on consumer ... as skin irritation resulting from consumer use,or possible misuse ... of the following Icy Hot Heat Therapy products,are affected ...
... forests, point to sedentary society, , , FRIDAy, Feb. 8 (HealthDay News) ... could go to connect with nature, but that healthy ideal may ... week,s issue of the Proceedings of the National Academies of ... may be down by as much as 25 percent since 1987. ...
Other Medicine News:Health News:Two Little Hands Productions, Creators of Popular Children's TV Series Signing Time, Debuts Second Season at This Year's Toy Fair 2008 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:Predictors of inaccurate online breast cancer information 2Health News:Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy 2Health News:Stop & Shop Alerts Customers to Voluntary Recall of Chattem Icy Hot Heat Therapy Products 2Health News:Americans Abandoning National Parks 2Health News:Americans Abandoning National Parks 3
... cystometry and urethral pressure profilometry. ... bladder to be filled while ... non-radiopaque catheter design enhances visualization ... sterile in peel-open packages. Intended ...
... desktop analyzer for fast point-of-care (POC) diagnosis ... vein thrombosis and/or pulmonary embolism. For use ... ,When every minute counts, the Cardiac ... troponin T, myoglobin, and D-Dimer from a ...
... with AMI symptoms and time is ... rapid, reliable and accurate solution for ... enhancement techniques, state-of-the-art fluorescence analysis, and ... delivers highly sensitive results without compromising ...
... SAFE-T-FILL Capillary Blood Collection Tubes are 100% ... a wide range of applications, the Capillary ... tube, attached cap and a micro tube.,The ... the blood into the micro tube thereby ...
Medicine Products: